Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Open-label Multicenter Exploratory Study to Assess Efficacy of Pembrolizumab Re-challenge as Second or Further Line in Patients With Advanced Non - Small Cell Lung Cancer

NCT03526887 is registered in ClinicalTrials.gov with Spanish Lung Cancer Group as lead sponsor.

NCT NCT03526887
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03526887 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Open-label Multicenter Exploratory Study to Assess Efficacy of Pembrolizumab Re-challenge as Second or Further Line in Patients With Advanced Non - Small Cell Lung Cancer
Lead sponsor
Spanish Lung Cancer Group
Phase
Phase 2
Overall status
Completed
Start date
July 15, 2018
Completion date
March 9, 2023
Enrollment
73 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer